Dreicer R
Department of Hematology, The Urologic Institute, Cleveland Clinic Foundation, OH 44195, USA.
Semin Urol Oncol. 2001 Aug;19(3):180-5.
Muscle-invasive bladder cancer is typically an aggressive solid tumor with the propensity for early systemic dissemination. Although radical cystectomy remains the gold standard intervention, the high rate of systemic failure has prompted investigators to evaluate various strategies to attempt to improve survival, including the early administration of systemic chemotherapy. These efforts have provided mixed results with two recently completed trials providing conflicting results. Other strategies include attempts to both preserve the bladder using combinations of limited surgical resection, systemic chemotherapy, and radiotherapy. This review focuses on the potential of neoadjuvantly administered therapies to impact the management of muscle-invasive bladder cancer.
肌层浸润性膀胱癌通常是一种侵袭性实体瘤，易于早期发生全身播散。尽管根治性膀胱切除术仍是金标准干预措施，但全身衰竭的高发生率促使研究人员评估各种策略以试图提高生存率，包括早期给予全身化疗。这些努力取得了喜忧参半的结果，最近完成的两项试验给出了相互矛盾的结果。其他策略包括尝试通过有限手术切除、全身化疗和放疗相结合的方式来保留膀胱。本综述重点关注新辅助治疗对肌层浸润性膀胱癌治疗的潜在影响。
